Приказ основних података о документу

dc.creatorGrahovac, J.
dc.creatorŽivić, K.
dc.creatorPavlović, M.
dc.creatorOstojić, M.
dc.creatorĐurić, A.
dc.creatorSrdić Rajić, T.
dc.creatorPavić, Aleksandar
dc.creatorGalun, D.
dc.date.accessioned2023-06-27T11:51:34Z
dc.date.available2023-06-27T11:51:34Z
dc.date.issued2023
dc.identifier.issn1574-7891
dc.identifier.issn1878-0261 (Online)
dc.identifier.urihttps://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.13471
dc.identifier.urihttps://imagine.imgge.bg.ac.rs/handle/123456789/1912
dc.description.abstractIntroduction: Pancreatic ductal adenocarcinoma (PDAC) has dismal prognosis, as there are no screening tests available, most often is diagnosed in the metastatic phase of the disease and is refractory to conventional, targeted and immunotherapy. We have examined the expression and role of the novel tumor suppressor nischarin (NISCH) in PDAC and the effects of treatment with the agonist rilmenidine (approved for treatment of hypertension) in order to determine the potential of nischarin agonists for repurposing in this deadly disease.sr
dc.language.isoensr
dc.publisherWileysr
dc.rightsopenAccesssr
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceMolecular oncologysr
dc.titlePreclinical validation of rilmenidine for repurposing in pancreatic ductal adenocarcinomasr
dc.typeconferenceObjectsr
dc.rights.licenseBYsr
dc.citation.epage348
dc.citation.issueSupplement 1
dc.citation.spage347
dc.citation.volume17
dc.description.otherEACR 2023: Innovative Cancer Science, 12-15 June 2023, Torino, Italysr
dc.identifier.doidoi.org/10.1002/1878-0261.13471
dc.identifier.fulltexthttps://imagine.imgge.bg.ac.rs/bitstream/id/261175/bitstream_261175.pdf
dc.type.versionpublishedVersionsr


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу